Evaluating the Effect of Silymarin on CAPD Patients

Not Applicable

• Conditions: N17-N19; Renal failure, peritoneal dyalisis.; Renal failure

• Registration Number: IRCT2013110315256N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Inclusion criterion: patients undergo Peritoneal Dialysis and are on the follow up of nephrologist at Emam reza Clinic between 18-60 years old.
Exclusion criteria:patients undergo Peritoneal Dialysis who had peritonitis in recent 2 month; hepatitis; or using other antioxidant, anti pregnancy, levothyroxin drugs and smoking.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glutathione peroxidase antioxidant enzyme in RBC. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant catalase enzyme. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant isoprostane enzye F2a. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant capacity FRAP. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.